IL6 and ovarian carcinoma: Numerous preclinical and translational studies emphasize the rational of targeting the IL-6/IL-6-signaling pathways in cancer, considering among others ovarian carcinoma, either as single treatment or in combination with other chemotherapeutic drugs [85, 86]; reviewed in [87].